Combunox (oxycodone HCl and ibuprofen) was approved by the FDA in November 2004 for the short-term (no more than seven days) management of acute, moderate to severe pain. Combunox is the first and only product to combine 5mg of oxycodone HCl and 400mg of ibuprofen, which is the highest dose of ibuprofen available in a combination opioid product.
Trial data has demonstrated that Combunox provides statistically superior pain relief compared to either of its individual components alone or placebo.
“Combunox is the first pain medication to combine the strength of oxycodone and ibuprofen, providing analgesia as well as anti-inflammatory properties,” said Dr Charles Argoff, a neurologist at North Shore University Hospital. “The combination of these two proven agents in one tablet provides physicians a powerful new option for addressing patients’ pain relief needs.”
Combunox was licensed to Forest by BTG Plc. Under terms of the licensing agreement, Forest is responsible for manufacturing, sales, and marketing activities of the product in the US. Forest also has marketing rights for the product in Canada and the UK, and sub-licensing rights in all other countries of the world.